Toggle light / dark theme

For more information on addiction services at #YaleMedicine, visit: https://www.yalemedicine.org/departments/program-in-addiction-medicine.

Written and produced by Yale Neuroscience PhD student Clara Liao.

Addiction is now understood to be a brain disease. Whether it’s alcohol, prescription pain pills, nicotine, gambling, or something else, overcoming an addiction isn’t as simple as just stopping or exercising greater control over impulses. That’s because addiction develops when the pleasure circuits in the brain get overwhelmed, in a way that can become chronic and sometimes even permanent. This is what’s at play when you hear about reward “systems” or “pathways” and the role of dopamine when it comes to addiction. But what does any of that really mean? One of the most primitive parts of the brain, the reward system, developed as a way to reinforce behaviors we need to survive—such as eating. When we eat foods, the reward pathways activate a chemical called dopamine, which, in turn, releases a jolt of satisfaction. This encourages you to eat again in the future. When a person develops an addiction to a substance, it’s because the brain has started to change. This happens because addictive substances trigger an outsized response when they reach the brain. Instead of a simple, pleasurable surge of dopamine, many drugs of abuse—such as opioids, cocaine, or nicotine—cause dopamine to flood the reward pathway, 10 times more than a natural reward. The brain remembers this surge and associates it with the addictive substance. However, with chronic use of the substance, over time the brain’s circuits adapt and become less sensitive to dopamine. Achieving that pleasurable sensation becomes increasingly important, but at the same time, you build tolerance and need more and more of that substance to generate the level of high you crave. Addiction can also cause problems with focus, memory, and learning, not to mention decision-making and judgement. Seeking drugs, therefore, is driven by habit—and not conscious, rational decisions. Unfortunately, the belief that people with addictions are simply making bad choices pervades. Furthermore, the use of stigmatizing language, such as “junkie” and “addict” and getting “clean,” often creates barriers when it comes to accessing treatment. There’s also stigma that surrounds treatment methods, creating additional challenges. Though treatment modalities differ based on an individual’s history and the particular addiction he or she has developed, medications can make all the difference. “A lot of people think that the goal of treatment for opioid use disorder, for example, is not taking any medication at all,” says David A. Fiellin, MD, a Yale Medicine primary care and addiction medicine specialist. “Research shows that medication-based treatments are the most effective treatment. Opioid use disorder is a medical condition just like depression, diabetes or hypertension, and as with those conditions, it is most effectively treated with a combination of medication and counseling.”

What happens in the brain when we feel threatened? Answers to this question could lead to new treatments for people with anxiety and panic disorders and PTSD. Caltech neuroscientist Dean Mobbs (http://www.hss.caltech.edu/people/dean-mobbs) studies how the brain processes different types of danger. In this video, Mobbs talks about fear, horror, and hope. Participants in his studies play virtual-predator video games inspired by horror movies while fMRI machines track the activity in their brains as they encounter threats. Mobbs and his research group recently showed that two regions of the brain are involved in processing fear: one for distant threats that allow some time to strategize, and one for immediate danger that requires a fight, flight, or freeze response. (Read more: https://www.caltech.edu/about/news/you-dont-think-your-way-o…tack-81542)

Mobbs conducts research in the Caltech Brain Imaging Center (http://cbic.caltech.edu), which is part of the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech (http://neuroscience.caltech.edu). Founded with a $115 million gift to Break Through: The Caltech Campaign (https://breakthrough.caltech.edu/) from visionary philanthropists Tianqiao Chen and Chrissy Luo, the Chen Institute at Caltech supports researchers who are deepening our understanding of the brain.

©2019 California Institute of Technology.

Antisocial Personality Disorder (ASPD) is a complex mental health condition characterized by a pervasive pattern of disregard for the rights of others and violation of societal norms. Untreated forms of ASPD affect about three percent of the general population. While the exact causes of ASPD remain unclear, researchers have identified several potential factors that may contribute to its development.

1. Genetic Factors: Studies suggest a genetic component in the development of ASPD, with heritability estimates ranging from 40% to 70%. Genetic variants involved in neurotransmitter regulation, such as serotonin and dopamine, have been implicated in antisocial behavior (Ficks & Waldman, 2014).

2. Environmental Factors: Childhood experiences play a crucial role in the development of ASPD. Early exposure to abuse, neglect, or inconsistent parenting has been linked to an increased risk of developing antisocial behavior (Rhee & Waldman, 2011).

Artificial intelligence is changing health care. It promises better diagnoses and fewer mistakes and all in less time. While some associate AI with a frightening dystopian future, many doctors see it as a source of support.

To help them care for patients, doctors are programming apps and supplying AI with data. At Berlin’s Charité hospital, Professor Surjo Soekadar is researching how neurotechnology might support paralysis patients in their everyday lives — for example, via assistance systems that are controlled via their thoughts.

This could offer hope to people like Guido Schule and Anne Nitzer had a stroke shortly after the birth of her second child and has been unable to move or speak since then — even though she is fully conscious.

At Vienna General Hospital (AKH) Professor Ursula Schmidt-Erfurth has already developed an AI-based diagnostic tool that has been licensed for use. Nowadays, she is researching how AI could improve both the diagnosis and the treatment of age-related macular degeneration (AMD). This chronic eye disease can lead to loss of vision — even with treatment. This is a fate that Oskar Zlamala could face. But since the retiree began treatment at the AKH Vienna, he is hoping that it might be possible to halt the progression of his illness.

Computer science experts and medics are also working together to help the Essen University Hospital go digital. Dr. Felix Nensa and Professor Arzu Oezcelik are improving care for transplant patients with the help of artificial intelligence. AI can calculate the size of organs, like the liver, for example, much more precisely and more quickly than people — and thereby improve outcomes and the safety of the procedure.

#documentary #dwdocumentary #health #artificialintelligence.

In September 2020 we sat down with Robert Sapolsky, Stanford professor and the author of Human Behavioral Biology lectures (https://youtu.be/NNnIGh9g6fA) to discuss if it’s possible for our society to reconcile our understanding of justice with scientific understanding of human behaviour.

Why do humans, most likely, have no free will? How does that link to depression and other psychiatric disorders? Can people accept the idea that there is no free will and start using, what science tells us about the reasons behind our behaviour, as a basis for making sense of justice and morality? If yes, can we even imagine what such society would look like?

This is a third interview with Robert. The first (https://youtu.be/VrQkl7PaA1s) and the second (https://youtu.be/yp9HE5xfojY) talks are available on our channel.

Notably, when implanted into mouse brains, the printed cells showed both structural and functional integration with the host tissue.

“Our droplet printing technique provides a means to engineer living 3D tissues with desired architectures, which brings us closer to the creation of personalised implantation treatments for brain injury,” said Dr Linna Zhou, senior author of the study.

The researchers now aim to further evolve their technique and create complex multi-layered cerebral cortex tissues that can mimic the human brain’s architecture in a more realistic way. Beyond brain injuries, these 3D-printed cells could benefit drug evaluation and our knowledge on brain development and cognition.

According to a new theory presented by researchers at HHMI’s Janelia Research Campus and their colleagues at University College London, how useful a memory is for future situations determines where it resides in the brain.

The theory offers a new way of understanding systems consolidation, a process that transfers certain memories from the hippocampus – where they are initially stored – to the neocortex — where they reside long term.

Under the classical view of systems consolidation, all memories move from the hippocampus to the neocortex over time. But this view doesn’t always hold up; research shows some memories permanently reside in the hippocampus and are never transferred to the neocortex.